Lymphangioleiomyomatosis is a congenital malformation of the lymphatic vasculature and was previously called lymphangioleiomyoma. The lymphangioleiomas are collectively referred to as lymphangioid malformations and are classified as microcystic and macrocystic types. It consists of dilated lymphatic vessels filled with clear fluid and containing small amounts of lymphocytes or even red blood cells lined with a single layer of flattened endothelial cells. The lesions increase in size with the age of the child and usually do not appear to subside on their own. The head and neck region is a common site of lymphatic duct malformation. Approximately 90% of lesions occur within 2 years of age and account for 6% of benign soft tissue lesions in people under 20 years of age. The cause is unknown, and most scholars believe that it is related to the underdevelopment of the lymphatic system. The impact of lymphatic duct malformations on the body depends on the site of occurrence, growth rate and size. Microcystic lymphatic duct malformations occur in the tongue, cheek, floor of the mouth, and tongue root, while large cystic types occur mainly in the neck, submandibular region, and floor of the mouth and are present at birth. Small lymphatic duct malformations may be asymptomatic and uncomfortable, while large ones may cause jaw deformity, cosmetic defects, or rapid enlargement due to infection, trauma, or bleeding causing respiratory pressure, difficulty in eating and speech, etc., leading to physical or psychological disorders, affecting the quality of life or even endangering life. The treatment of lymphatic duct malformation currently includes interventional sclerosis, laser and surgery. Surgical treatment is suitable for large cystic type, and most of them can be completely removed, but because of the thin wall of lymphatic duct malformation, it is easy to be torn during surgery, and it is often connected with important structures and has local infiltration, so the surgery is easy to damage important blood vessels and nerves, and the complication rate is 12%-33%, and the resection is not complete and easy to recur, and the recurrence rate is 15%-53%. The serious complications of surgery and high recurrence rate bring great difficulties to clinical treatment. Laser treatment is suitable for superficial mucosal lesions, but the vesicles of most lymphangioleiomyomatous lesions are often connected to deep, dilated pools that often penetrate deep into the muscle tissue. Due to this pathological feature of lymphangioleiomyomatosis and the limitation of laser penetration depth, deep lesions are difficult to eradicate and prone to recurrence. Currently, interventional sclerotherapy is widely used in clinical practice. Interventional sclerotherapy has the advantages of being minimally invasive, economical, reproducible, and effective. Sclerotherapy includes sodium cod liver oil, tetracycline, anhydrous ethanol, alcoholic protein, elimination of hemorrhoids, urea, etc. In recent years, the sclerotherapy agents that have been used more often, have fewer complications and have positive efficacy are bleomycin and hemolytic streptococcal preparation (0K-432). The domestic production of pinyamycin and sapropterin are the same kind of drugs as bleomycin and 0K I 432 respectively. In addition to inhibiting the proliferation of lymphatic endothelial cells and making the tumor disappear, the sclerosing agent can also lead to the local accumulation of drugs due to the injection in the lumen, and the chemical stimulation of high concentration of drugs can destroy the epithelial cells in the inner wall of the lymphatic duct malformation and make them necrotic and fall off, resulting in sterile inflammation in the capsule, leading to the proliferation of connective tissue and the formation of scarring fibrous adhesions and occlusion, so that the lumen will gradually absorb and shrink. Our department has completed nearly 1,000 cases of interventional sclerotherapy for lymphatic duct malformation in children, and has achieved promising results. We suggest that interventional sclerotherapy should be preferred for large cystic lymphatic duct malformations. The microcystic type can also be treated with interventional sclerotherapy first and then combined with surgical resection.